Blanca Hernando - Search Results

Year	Number of Results
2011	1
2012	1
2013	2
2014	1
2015	4
2020	3
2021	0

1

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Goss PE, et al. N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. N Engl J Med. 2011. PMID: 21639806 Free article. Clinical Trial.

2

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype.

Lope V, Guerrero-Zotano Á, Casas A, Baena-Cañada JM, Bermejo B, Pérez-Gómez B, Criado-Navarro I, Antolín S, Sánchez-Rovira P, Ramos-Vázquez M, Antón A, Castelló A, García-Saénz JÁ, Muñoz M, de Juan A, Andrés R, Llombart-Cussac A, Hernando B, Franquesa RM, Caballero R, Priego-Capote F, Martín M, Pollán M. Lope V, et al. Among authors: hernando b. Nutrients. 2020 Oct 14;12(10):3132. doi: 10.3390/nu12103132. Nutrients. 2020. PMID: 33066483 Free PMC article.

3

Palbociclib combined with endocrine therapy in heavily pretreated HR⁺/HER2^- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).

Manso L, Hernando C, Galán M, Oliveira M, Cabrera MA, Bratos R, Rodríguez CA, Ruiz-Borrego M, Blanch S, Llombart-Cussac A, Delgado-Mingorance JI, Álvarez-Busto I, Gallegos I, González-Cortijo L, Morales S, Aguirre E, Hernando BA, Ballesteros A, Alés-Martínez JE, Reboredo C, Oltra A, González-Cao M, Santisteban M, Malón D, Echeverría I, García-Garre E, Vega E, Servitja S, Andrés R, Robles CE, López R, Galve E, Echarri MJ, Legeren M, Moreno F. Manso L, et al. Among authors: hernando ba. Breast. 2020 Dec;54:286-292. doi: 10.1016/j.breast.2020.11.005. Epub 2020 Nov 13. Breast. 2020. PMID: 33242755 Free PMC article.

4

A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection.

Velázquez C, Lastra E, Avila Cobos F, Abella L, de la Cruz V, Hernando BA, Hernández L, Martínez N, Infante M, Durán M. Velázquez C, et al. Among authors: hernando ba. J Transl Med. 2020 Jun 10;18(1):232. doi: 10.1186/s12967-020-02391-z. J Transl Med. 2020. PMID: 32522261 Free PMC article.

5

Morphological, Chemical Surface, and Diffusive Transport Characterizations of a Nanoporous Alumina Membrane.

Vázquez MI, Romero V, Vega V, García J, Prida VM, Hernando B, Benavente J. Vázquez MI, et al. Among authors: hernando b. Nanomaterials (Basel). 2015 Dec 5;5(4):2192-2202. doi: 10.3390/nano5042192. Nanomaterials (Basel). 2015. PMID: 28347115 Free PMC article.

6

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.

Martín M, Martínez N, Ramos M, Calvo L, Lluch A, Zamora P, Muñoz M, Carrasco E, Caballero R, García-Sáenz JÁ, Guerra E, Caronia D, Casado A, Ruíz-Borrego M, Hernando B, Chacón JI, De la Torre-Montero JC, Jimeno MÁ, Heras L, Alonso R, De la Haba J, Pita G, Constenla M, González-Neira A. Martín M, et al. Among authors: hernando b. Oncologist. 2015 Feb;20(2):111-2. doi: 10.1634/theoncologist.2014-0379. Epub 2015 Jan 19. Oncologist. 2015. PMID: 25601966 Free PMC article. Clinical Trial.

7

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A. Martín M, et al. Among authors: hernando b. J Clin Oncol. 2013 Jul 10;31(20):2593-9. doi: 10.1200/JCO.2012.46.9841. Epub 2013 Jun 3. J Clin Oncol. 2013. PMID: 23733779 Clinical Trial.

8

Changes in morphology and ionic transport induced by ALD SiO₂ coating of nanoporous alumina membranes.

Romero V, Vega V, García J, Zierold R, Nielsch K, Prida VM, Hernando B, Benavente J. Romero V, et al. Among authors: hernando b. ACS Appl Mater Interfaces. 2013 May;5(9):3556-64. doi: 10.1021/am400300r. Epub 2013 Apr 25. ACS Appl Mater Interfaces. 2013. PMID: 23574388

9

Unveiling the Hard Anodization Regime of Aluminum: Insight into Nanopores Self-Organization and Growth Mechanism.

Vega V, García J, Montero-Moreno JM, Hernando B, Bachmann J, Prida VM, Nielsch K. Vega V, et al. Among authors: hernando b. ACS Appl Mater Interfaces. 2015 Dec 30;7(51):28682-92. doi: 10.1021/acsami.5b10712. Epub 2015 Dec 18. ACS Appl Mater Interfaces. 2015. PMID: 26646814

10

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.

Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Sánchez P, Ramos M, Antón A, Muñoz M, Bermejo B, De Juan-Ferré A, Jara C, Chacón JI, Jimeno MA, Rosado P, Díaz E, Guillem V, Lluch A, Carrasco E, Pérez-Gómez B, Vioque J, Pollán M; EpiGEICAM Researchers. Castelló A, et al. PLoS One. 2015 May 15;10(5):e0126096. doi: 10.1371/journal.pone.0126096. eCollection 2015. PLoS One. 2015. PMID: 25978407 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results